Accepted Manuscript

Original article

Deleterious effects of Potassium bromate administration on renal and hepatic tissues of Swiss Mice

Naif G. Altoom, Jamaan Ajarem, Ahmed A. Allam, Saleh N. Maodaa, Mostafa A. Abdel- Maksoud

PII: S1319-562X(17)30071-2
DOI: http://dx.doi.org/10.1016/j.sjbs.2017.01.060
Reference: SJBS 905

To appear in: Saudi Journal of Biological Sciences

Received Date: 19 January 2016
Revised Date: 29 January 2017
Accepted Date: 30 January 2017

Please cite this article as: N.G. Altoom, J. Ajarem, A.A. Allam, S.N. Maodaa, M.A. Abdel- Maksoud, Deleterious effects of Potassium bromate administration on renal and hepatic tissues of Swiss Mice, Saudi Journal of Biological Sciences (2017), doi: http://dx.doi.org/10.1016/j.sjbs.2017.01.060

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
Deleterious effects of Potassium bromate administration on renal and hepatic tissues of Swiss Mice

Naif G. Altoom¹, Jamaan Ajarem¹, Ahmed A. Allam¹,², Saleh N Maodaa¹, Mostafa A. Abdel-Maksoud¹*

¹King Saud University, College of Science, Department of Zoology, Riyadh 11451, Saudi Arabia
²Beni-Suef University, Faculty of Science, Department of Zoology, Beni-Suef, Egypt
*Correspondence to: Mostafa A. Abdel-Maksoud, PhD in Immunology, Zoology Department, College of Science, King Saud University.
P.O. Box 2455, Riyadh – 11451, Saudi Arabia.
Tel: 00966507927800    Fax: 0096614679781
E-mail: harrany@gmail.com
Mostafa A. Abdel-Maksoud: harrany@ gmail.com
Jamaan Ajarem: jajarem@ksu.edu.sa
Naif Altoom: nalotaiby1@hotmail.com
Ahmed Allam: aallam@ksu.edu.sa
Saleh Maodaa: maodaa_28@yahoo.com
Deleterious effects of Potassium bromate administration on renal and hepatic tissues of Swiss Mice

Abstract

Potassium bromate (KBrO₃) is widely used as a food additive and is a major water disinfection by-product. The present study reports the side effects of KBrO₃ administration in Swiss mice. Animals were randomly divided into three groups: control, low dose KBrO₃ (100 mg/kg/day) and high dose KBrO₃ (200 mg/kg/day) groups. Administration of KBrO₃ led to decreased white blood corpuscles (WBCs), red blood corpuscles (RBCs) and platelets count in the animals of both the high and the low dose groups. Altered lipid profile represented as low density lipoprotein (LDL), high density lipoprotein (HDL) and cholesterol levels were observed in plasma samples of both KBrO₃ treated groups of mice. Also, an increased plasma level of LDH was detected in both KBrO₃ treated groups. Histological investigations showed impaired renal and hepatic histology that was concomitant with increased plasma Creatinine level in both of KBrO₃-treated groups. Nevertheless, decreased glutathione (GSH) level in both renal and hepatic tissue of mice after KBrO₃ intake was detected. These results show that KBrO₃ has serious damaging effects and therefore, its use should be avoided.

Keywords: Platelets, Lipid profile, LDH, Creatinine, Reduced glutathione
1. Introduction

Potassium bromate (KBrO₃) is a well-known flour improver that acts as a maturing agent (Vadlamani and Seib, 1999). It has been in use as a food additive for the past 90 years (Oloyede and Sunmonu, 2009). It acts principally in the late dough stage giving strength and elasticity to the dough during the baking process while also promoting the rise of bread. KBrO₃ is also used in beer making, cheese production and is commonly added to fish paste products (Ahmad and Mahmood, 2014). Additionally, it is used in pharmaceutical and cosmetic industries and is a constituent of cold wave hair solutions (Oloyede and Sunmonu, 2009). Moreover, KBrO₃ can appear as a byproduct in an ozonization of water containing bromide. As a result of KBrO₃ biotransformation, free radicals generation can cause oxidative damage to essential cellular macromolecules, leading to marked nephrotoxicity and cancer in experimental animals (Chipman et al., 1998). International Agency for Research on Cancer (IARC) has classified KBrO₃ as a possible human carcinogen (group 2B) (IARC, 1999) and its application in food processing was restricted. Indeed, many previous reports has documented that KBrO₃ can induce multiple organ toxicity in humans and experimental animals (Farombi et al., 2002; Kujawska et al., 2013; Ahmad et al., 2015) and that kidney is considered to be the primary target organ of these dangerous compound (Kurokawa et al., 1990; Ahmad et al., 2013). KBrO₃ is extremely irritating and injurious to tissues especially those of the central nervous system (CNS) and kidneys. The pathological findings included renal tissue damage and haemolysis (Robert and William, 1996). Carcinogenic and mutagenic effects of KBrO₃ have been also reported in experimental animals (Kurokawa et al., 1987). Several cases of accidental poisoning in children resulting from ingestion of
bromate solution and sugar contaminated with bromate were reported as the source of an outbreak of mild poisoning in New Zealand (Paul, 1966). Consequently, KBrO$_3$ has been banned in several countries including the United Kingdom in 1990, Nigeria in 1993 and Canada in 1994 (Oloyede and Sunmonu, 2009). Toxicological studies have convincingly shown that KBrO$_3$ affects the nutritional quality of bread as the main vitamins available in bread are degraded (Sai et al., 1992). Oral doses of 185–385 mg/kg body weight results in irreversible toxic effects like renal failure and deafness in humans while lower doses are accompanied with vomiting, diarrhea, nausea and abdominal pain (Mark, 1988). It is known that KBrO$_3$ induces oxidative stress in tissues (Sai et al., 1991; Watanabe et al., 1992; Parsons and Chipman, 1992, 2000) that could be the basis of bromate-induced carcinogenesis (Chipman et al., 2006). The present study attempts to assess the effects of oral administration of KBrO$_3$ on the lipid profile in plasma, oxidative stress, hepatic and renal histomorphology of Swiss mice using two different doses of KBrO$_3$ to compare their effects.
2. Materials and Methods

2.1. Animals

Forty five (45) Swiss Webster (SW) mice were obtained from animal house- College of pharmacy- king Saud University and maintained and monitored in a specific pathogen-free environment. All animal procedures were performed in accordance with the standards set forth in the Guidelines for the Care and Use of Experimental Animals issued by the Committee for the Purpose of Control and Supervision of Experiments on Animals (CPCSEA). The study protocol was approved by the Animal Ethics Committee at King Saud University. All animals were allowed to acclimatize in plastic cages inside a well-ventilated room for one week prior to the experiment. The animals were maintained under standard laboratory conditions (temperature of 23°C, relative humidity of 60–70% and a 12-hour light/dark cycle), fed a diet of standard commercial pellets and given water ad libitum.

2.2. KBrO₃ Preparation and dosing schedule

Potassium bromate salt, a product of British drug home limited, Poole England was supplied in its white crystalline form by ASILA chemicals (Saudi Arabia). It was then dissolved in water to prepare the 100 mg/kg dose (0.5 gm/L) and the 200 mg/kg dose (1 gm/L). Animals were divided into 3 groups as follows: Group (I) control group (was given distilled water); Group (II) Low dose KBrO₃ group (was given 100 mg/kg); Group (III) High dose KBrO₃ group (was given 200 mg/kg). KBrO₃ was orally administered daily through oral intubation at the two doses of 100 and 200 mg/kg/day for 42 days.
2.3. Sample collection
Blood was collected from the heart in heparinized tubes and plasma was obtained for biochemical investigations. Plasma was stored at −80°C until use. Small pieces of liver and kidneys were removed, cut and put in sterile saline. The pieces were then fixed in 10% neutral buffered formalin and then embedded in paraffin.

2.4. Histological analysis of hepatic and renal tissues
The preparation of tissues for histological examination was done as described by Krause (2001); the photomicrographs were observed using the Leitz, DIALUX research microscope at x200. Pathological evaluation in H/E stained tissue sections was done by a pathologist blinded for the experimental regimen.

2.5. Cell Blood Count (CBC)
Whole blood samples were analyzed with an automatic Vet abc™ Animal Blood Counter (Horiba ABX, Montpellier, France) using the hematology kits specified for that instrument (Horiba ABX, France) according to the manufacturer’s instructions.

2.6. Determination of Creatinine level in plasma
Plasma samples were analyzed using commercial kits (bioMerieux, Marcy l’Etoile, France) for Creatinine according to the instructions of the manufacturer. Absorbance was measured with an Ultrospec 2000 U/V spectrophotometer (Amersham Pharmacia Biotech, Cambridge, England).

2.7. Lactate dehydrogenase (LDH)
Lactate dehydrogenase was determined using specified kits LiquiUV Test (Human, Germany) according to the manufacturer’s instructions. Briefly, 20 µl of plasma was added to 1000 µl buffer solution (provided by in the kit) then incubated in cuvettes for 5
minutes at 30° C. After that, 250 µl of the substrate was mixed with the solution and the absorbance was monitored after 1, 2 and 3 minutes. The colour development was detected at 340 nm in a spectrophotometer.

2.8. Lipid Profile in Plasma

LDL, HDL and total cholesterol levels were measured by an enzymatic colorimetric kit (Wako Chemicals USA, Inc.). Briefly, 10 µl of plasma were put into tubes and 1 ml of colour reagent solution was then added. 10 µl of standard solution (provided by in the kit), were put into tubes and 1 ml of colour reagent solution was then added. The solution was mixed well and incubated at 37°C for 5 min. The colour development was detected at 500 nm in a spectrophotometer.

2.9. Glutathione (GSH) assay

Glutathione content was determined according to the procedure of Beutler et al. (1963) with some modification. Briefly, 0.20 ml of tissue supernatant was mixed with 1.5 ml precipitating solution containing 1.67% glacial metaphosphoric acid, 0.20% Na-EDTA and 30% NaCl. The mixture was allowed to stand for 5 min at room temperature and centrifuged 1,000 g for 5 min. One ml clear supernatant was mixed with 4 ml 0.30 M Na₂HPO₄ and 0.50 ml DTNB reagent (40 mg 5, 5’dithiobis-(2-nitrobenzoic acid dissolved in 1% sodium citrate). A blank was similarly prepared in which 0.20 ml water was used instead of the brain supernatant. The absorbance of the color was measure at 412 nm in a spectrophotometer.

2.10. Statistical analysis

Prior to further statistical analysis, the data were tested for normality using the Anderson-Darling test, as well as for homogeneity variances. The data was normally distributed and
is expressed as the mean ± standard error of the mean (SEM). Significant differences among the groups were analysed by one- or two-way ANOVA followed by Bonferroni’s test for multiple comparisons using PRISM statistical software (GraphPad Software). The data was also reanalysed by one- or two-way ANOVA followed by Tukey’s post-test using SPSS software, version 17. Differences were considered statistically significant at P<0.05.
3. Results

3.1. Decreased WBCs, RBCs and platelets count after KBrO₃ intake

WBCs count was significantly decreased in both of KBrO₃ treated groups. As shown in table 1, the low dose of KBrO₃ was associated with a lower number of WBCs in comparison to the control group. Additionally, the high dose of KBrO₃ was accompanied with a much more decrease in the WBCs count in comparison to either the control or the low dose group. RBCs count was also decreased in the low dose KBrO₃ group in comparison to the control group. Similarly, the decrease in RBCs count was higher in the high dose KBrO₃ group in comparison to both the low dose and the control one. Platelets count was having a similar pattern of decrease in both of KBrO₃ treated groups. A significantly decreased Platelets count was detected in the low dose KBrO₃ group. On the other hand, the high dose KBrO₃ group has showed a lower platelets count in comparison to either the control group or the low dose KBrO₃ group.

3.2. Altered lipid profile in plasma of KBrO₃ treated mice

Disturbance in lipid profile in plasma is considered as an indicator for many physiological disorders. LDL, HDL and cholesterol levels in plasma samples of the three experimental groups were investigated. Both of the low and the high doses of KBrO₃ were accompanied with a significant reduction in the plasma concentrations of HDL (Figure 1a). Conversely, the plasma level of LDL was increased in both of the low and the high dose KBrO₃ groups. A significant increase was detected in the high dose KBrO₃ group in comparison to the control group (Figure 1b). Nevertheless, the change in the plasma level of cholesterol (Figure 1c) in both of KBrO₃ groups was not significant in comparison to the control group.

3.3. KBrO₃ treatment was associated with an increased plasma level of LDH
LDH is often used as a marker of tissue breakdown and can function as an indicator for liver toxicity. Figure 2 illustrates that both groups of the high and the low doses of potassium bromate were associated with a significant increase in the plasma level of LDH in comparison to the control group. However, the high dose of potassium bromate was accompanied with a much more increase in the LDH level in comparison to either the control or the low dose group.

### 3.4. Impaired hepatic and renal histology concomitant with increased plasma Creatinine in both KBrO₃ groups

As a result of KBrO₃ treatment, hepatic tissue sections of KBrO₃ treated mice have showed a congestion of central vein with a relative increase in Kupffer cells (KCs) in comparison to the control group (Figure 3). Renal tissue of KBrO₃ treated group of mice was largely affected in comparison to the control group. Hemorrhage was seen in both KBrO₃ treated groups. Dilated blood vessels were seen in the high dose KBrO₃ treated group (Figure 4). To confirm these findings, Creatinine level in plasma, which is considered as an important indicator for kidney function, was determined. As illustrated in figure 5, a significant increase in the plasma level of Creatinine in both of KBrO₃ treated groups was detected. The low dose group had a higher plasma level of Creatinine in comparison to the control. The high dose group has exhibited a much more increase in the plasma level of Creatinine in comparison to both the control and the low dose one.

### 3.5. Decreased glutathione level in both renal and hepatic tissues of KBrO₃ treated mice.

Reduced glutathione (GSH) is an important antioxidant that plays a crucial role in nearly all living organisms. KBrO₃ treatment had a negative impact on both the renal and the hepatic level of this important molecule. In the low dose KBrO₃ group, both of the renal and the hepatic levels of GSH were significantly decreased in comparison to that of the control group. At the same time,
a significant reduction in the level of this crucial molecule was also monitored in both the renal and hepatic homogenates of the high dose KBrO₃ group in comparison to either the control group or the low dose KBrO₃ group (Figure 6).
4. Discussion

Potassium bromate (KBrO$_3$) is widely used as improving additive for bread making (Ahmad et al., 2015) and marketed as a neutralizer in home permanent cold wave hair kits that caused several cases of accidental poisoning in children resulting from the ingestion of this solution (Paul, 1966). Due to its hazardous effects, it has been forbidden in various countries (Oloyede and Sunmonu, 2009). Toxicity studies in animals are commonly used to assess potential health risk in humans caused by intrinsic adverse effects of chemical compounds (Kurokawa et al., 1990). These adverse effects may manifest significant alterations in the levels of bio molecules, normal functioning and histomorphology of the organs (Ahmad et al., 2014). The current study was designed to investigate some of the biochemical changes induced by KBrO$_3$ intake in Swiss Mice. We have observed that the total reticulocyte, leukocyte and platelet counts in the plasma samples of both KBrO$_3$ treated groups have been significantly decreased in comparison to the control group. These reductions in the leukocyte and platelet counts could be due to the DNA strand breakage in these cells induced by the oxidative stress associated with KBrO$_3$, (Chipman et al. 1998, Sai et al.2000, Parson and Chipman, 2000, Thompson and Westfall 1949). Furthermore, there could have been bone marrow suppression with selective megakaryocytic depression (Hoffbrand et al.2004). So, the reductions in the RBCs, WBCs and platelets could imply selective systemic toxicity effect by KBrO$_3$. Lipid profile represents an important indicator of several pathological conditions. The most common metabolic contributor to the coronary artery disease is the atherogenic lipoprotein profile, characterized by an increased LDL level and a deficiency of HDL level (Superko et al., 2002). Many studies have reported that increased level of LDL is associated with higher risk of atherosclerosis while elevated level of HDL is linked to reduced occurrences of cardiovascular disorders (Grover-Paez and Zavalza-omez, 2009; Olukanni et al., 2013). In the current study, the level of plasma HDL decreased with both doses of KBrO$_3$ leading to elevated atherogenic index which can be used to predict the risk for development of
cardiovascular disorders. Therefore, the high ratio of LDL to HDL, caused by KBrO3, may implicate increased tendency for the development of atherosclerosis. LDH is considered as a liver toxicity indicator and the increased LDH level in KBrO3 groups that has been observed in the current study is in accordance with previous reports (Ahmad et al., 2014). In another study, KBrO3 induced chromosomal aberrations (CA) and decreased both the cell proliferation index (PI) and the mitotic index (MI) of human peripheral lymphocytes in vitro (Kaya and Topaktaş, 2007). Histological observation of hepatic tissue sections has confirmed the liver pathology due to KBrO3. Previous studies have illustrated that KBrO3 treatment in wister rats have hepatotoxic effects (Oyewo et al., 2013). KBrO3-mediated renal injury in Wistar rats was also recorded before (Khan and Sultana, 2005). In the current study, histological findings in renal tissue of KBrO3 treated groups were supported by previous reports (Kurokawa et al., 1990). A dose-dependent increase in the numbers of eosinophilic droplets within the proximal tubule epithelium was observed in male F344 rats exposed to 20,100, 200, or 400mg/L KBrO3 for 12 weeks (Wolf, 1998). Kurokawa et al. (1987) reported similar lesions in proximal renal tubules of male F344 rats following 13 weeks exposure of 500mg/L KBrO3. In addition to that, Dodd et al (2013) have reported similar results in the same animal model. So the results in the current study agree very well with the results of these sub chronic studies. Elevated levels of Creatinine in plasma were observed confirming previous reports that KBrO3 ingestion causes acute kidney damage (Kurokawa et al., 1990; Bao et al., 2008). Reduced glutathione is an important antioxidant molecule that can be used by many organs, including kidney and liver, to withstand the induced oxidative stress. Previous studies have illustrated that KBrO3 can decrease the tissue content of this molecule (Chipman et al., 1998; Parsons and Chipman, 2000). In agreement with these previous results, the current study illustrated that renal and hepatic levels of GSH have been reduced after KBrO3 treatment with more reduction in the high dose KBrO3 group in comparison to the low dose one. A similar effect has been observed in our previous study in brain tissue
Taken together, our data reveals that KBrO$_3$ has several harmful effects on the biochemical and histological levels and therefore, its consumption should be prohibited.

5. Conclusions

KBrO$_3$ treatment in Swiss Mice has several consequences like disturbance in blood biochemistry, renal and hepatic histopathology and decreased antioxidant capacity. These dangerous effects should stop its use in human being.

Competing interests:

The authors declare no conflicts of interest. This manuscript has not been published or submitted elsewhere. This work complies with the Ethical Policies of the Journal and has been conducted under internationally accepted ethical standards following relevant ethical review.

Acknowledgments:

The authors would like to extend their sincere appreciation to the Deanship of Scientific Research at King Saud University for its funding of this research through the Research Group Project no RGP- VPP-240.

Authors' contributions:

NGA put the design of the experiment and carried out all the lab work, preparing the figures and drafted the manuscript. JA participated in the design of the study and helped to draft the manuscript. AA participated in the design of the study and helped to draft the manuscript. SNM participated in the design of the study, participated in the figures preparation and helped to draft and edit the manuscript. MAM
participated in the design of the study, helped to perform the statistical analysis and helped to draft the manuscript.

References


Chipman, J.K., Davies, J.E., Parsons, J.L, Nair, J., O’Neill, G., Fawell, J.K., 1998. DNA oxidation by potassium bromate; a direct mechanism or linked to lipid peroxidation? Toxicology 126, 93-102.


Parsons, J.L., Chipman, J.K., 1992. DNA oxidation by potassium bromate: a direct mechanism or linked to peroxidation. Toxicology 126, 93–102.


Table and Figure legends:

**Figure 1**: Effect of KBrO\textsubscript{3} on the lipid profile in plasma samples of treated mice using two different doses of KBrO\textsubscript{3}. (a) Plasma level of high density lipoprotein, (b) Plasma level of low density lipoprotein, (c) Plasma level of cholesterol. The data are the mean ±SEM for 10 mice per group. *P* < 0.05 for low dose KBrO\textsubscript{3} treated group vs. control group; #P < 0.05 for high dose KBrO\textsubscript{3} treated group vs. control group; +P < 0.05 for high dose KBrO\textsubscript{3} treated group vs. low dose KBrO\textsubscript{3} treated group.

**Figure 2**: Effect of KBrO\textsubscript{3} on the lactate dehydrogenase level in plasma samples of treated mice. The data are the mean ±SEM for 10 mice per group. *P* < 0.05 for low dose KBrO\textsubscript{3} treated group vs. control group; #P < 0.05 for high dose KBrO\textsubscript{3} treated group vs.
control group; $^+P<0.05$ for high dose KBrO$_3$ treated group vs. low dose KBrO$_3$ treated group.

**Figure 3:** Effect of KBrO$_3$ on the histology of liver. Sections of liver showing central vein (CV), congested central vein (CCV), hepatic sinusoid (S), vacuoles (V), hepatic cell (HIC), Kupffer cell (KC). (A, B) control group, (C, D) potassium bromate100 mg/kg group, (E, F) potassium bromate200 mg/kg group. Scale bar = 400 μm in A, C, E and 50 μm in B, D, F.

**Figure 4:** Effect of KBrO$_3$ on the histology of kidney. Sections in the kidney showing the kidney tubules (arrow head), Bowman's capsule (arrow), Hemorrhage (H) and dilated blood vessels (DV). (A, B) control group, (C, D) potassium bromate100 mg/kg group, (E, F) potassium bromate200 mg/kg group. (H & E stain, Scale bar = 200 μm in A, C, E and 50 μm in B, D, F).

**Figure 5:** Effect of KBrO$_3$ on the plasma level of Creatinine. The data are the mean ±SEM for 10 mice per group. $^*P<0.05$ for low dose KBrO$_3$ treated group vs. control group; $^#P<0.05$ for high dose KBrO$_3$ treated group vs. control group; $^+P<0.05$ for high dose KBrO$_3$ treated group vs. low dose KBrO$_3$ treated group.

**Figure 6:** Effect of KBrO$_3$ on the hepatic and renal level of GSH. The data are the mean ±SEM for 10 mice per group. $^*P<0.05$ for low dose KBrO$_3$ treated group vs. control group; $^#P<0.05$ for high dose KBrO$_3$ treated group vs. control group; $^+P<0.05$ for high dose KBrO$_3$ treated group vs. low dose KBrO$_3$ treated group.

**Table 1:** Effect of KBrO$_3$ treatment on the RBCs, WBCs and platelets count. RBCs, WBCs and platelets count were measured in the three groups of mice, and the results are presented as the means ± SEM (n=10), $^*P<0.05$ for low dose KBrO$_3$ group vs. control; $^#P<0.05$ for high dose KBrO$_3$ group vs. control.
Table 1

<table>
<thead>
<tr>
<th></th>
<th>Mean Total Leukocyte Count (x10^9/L)</th>
<th>Mean Total Reticulocyte Count (x10^9/L)</th>
<th>Mean Platelet Count (x10^9/L)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control</td>
<td>11.3 ± 0.62</td>
<td>8.3352 ± 0.13200</td>
<td>875 ± 38</td>
</tr>
<tr>
<td>KBrO₃ (100mg/dl)</td>
<td>10.0 ± 0.58*</td>
<td>7.2550 ± 0.3294*</td>
<td>423 ± 42*</td>
</tr>
<tr>
<td>KBrO₃ (200mg/dl)</td>
<td>9.5 ± 0.93#</td>
<td>7.1375 ± 0.4019#</td>
<td>405 ± 63#</td>
</tr>
</tbody>
</table>
Figure 1

A

Mean of HDL (mg/dL)

C - Control
T1 - potassium bromate 100 mg/kg
T2 - potassium bromate 200 mg/kg

**

B

Mean of LDL (mg/dL)

C - Control
T1
T2

#

C

Mean of cholesterol (mg/dL/protein/min)

C - Control
T1
T2

#
Figure 2

Mean of LDH (nmoles/mg protein/min)

C - Control
T1 - potassium bromate 100 mg/kg
T2 - potassium bromate 200 mg/kg

Treatment groups
Figure 3
Figure 4

[A] Image showing a section of tissue with labeled structures.
[B] Image showing a magnified section of tissue with labeled structures.
[C] Image showing a different section of tissue with labeled structures.
[D] Image showing a further magnified section of tissue with labeled structures.
[E] Image showing an even more magnified section of tissue with labeled structures.
[F] Image showing the outermost magnification of tissue with labeled structures.
Figure 5

**Figure 5**

![Graph showing mean creatinine levels in different treatment groups](image)

- **C** - Control
- **T1** - Potassium bromate 100 mg/kg
- **T2** - Potassium bromate 200 mg/kg

The graph illustrates the mean creatinine levels in mg/dL across different treatment groups. Significant differences are indicated by "**" and "##".
Figure 6

Control
T1- potassium bromate 100 mg / kg
T2- potassium bromate 200 mg / kg